{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:02:59Z","timestamp":1788973379876,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jchromb.2021.123076","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T12:07:12Z","timestamp":1638360432000},"page":"123076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS\/MS"],"prefix":"10.1016","volume":"1188","author":[{"given":"Jens","family":"Martens-Lobenhoffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie M.","family":"Bode-B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jchromb.2021.123076_b0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jchromb.2021.123076_b0010","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212595","article-title":"Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis","volume":"8","author":"Biggioggero","year":"2019","journal-title":"Drugs in Context"},{"issue":"5","key":"10.1016\/j.jchromb.2021.123076_b0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","article-title":"A review of upadacitinib in rheumatoid arthritis","volume":"30","author":"Tanaka","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jchromb.2021.123076_b0020","doi-asserted-by":"crossref","unstructured":"A.B. Avci, E. Feist, G.R. Burmester, Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis, Rheumatology 60 (2021) ii11-ii16.","DOI":"10.1093\/rheumatology\/keaa893"},{"key":"10.1016\/j.jchromb.2021.123076_b0025","unstructured":"Rinvoq | European Medicines Agency, 2021, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rinvoq, accessed 18 August 2021."},{"key":"10.1016\/j.jchromb.2021.123076_b0030","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.jchromb.2021.123076_b0035","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jchromb.2021.123076_b0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40262-019-00855-0","article-title":"Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication","volume":"59","author":"Mohamed","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.123076_b0045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/FTD.0000000000000421","article-title":"Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis","volume":"39","author":"Medina","year":"2017","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.jchromb.2021.123076_b0050","doi-asserted-by":"crossref","first-page":"e4159","DOI":"10.1002\/bmc.4159","article-title":"Liquid chromatographic methods for the therapeutic drug monitoring of methotrexate as clinical decision support for personalized medicine: A brief review","volume":"32","author":"Silva","year":"2018","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2021.123076_b0055","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/molecules25071600","article-title":"A Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats","volume":"25","author":"Ezzeldin","year":"2020","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.jchromb.2021.123076_b0060","doi-asserted-by":"crossref","first-page":"e4458","DOI":"10.1002\/bmc.4458","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS assay for the quantification of tofacitinib in human plasma","volume":"33","author":"Bharwad","year":"2019","journal-title":"Biomed. Chromatogr."},{"issue":"12","key":"10.1016\/j.jchromb.2021.123076_b0065","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","article-title":"Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis","volume":"55","author":"Mohamed","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2021.123076_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113386","article-title":"Development of UPLC-MS\/MS method for studying the pharmacokinetic interactions of pexidartinib with antifungal drugs in rats","volume":"188","author":"Shi","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"2","key":"10.1016\/j.jchromb.2021.123076_b0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.462","article-title":"Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials","volume":"8","author":"Mohamed","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jchromb.2021.123076_b0080","unstructured":"Turalio | European Medicines Agency, 2021, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/turalio, accessed 7 September 2021."},{"key":"10.1016\/j.jchromb.2021.123076_b0085","unstructured":"Bioanalytical method validation | European Medicines Agency, 2020, https:\/\/www.ema.europa.eu\/en\/bioanalytical-method-validation, accessed 4 November 2020."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221005572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023221005572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:06:40Z","timestamp":1761606400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023221005572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":17,"alternative-id":["S1570023221005572"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.123076","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS\/MS","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2021.123076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123076"}}